EZZ Life Science Holdings Ltd
ASX:EZZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (1), the stock would be worth AU$1.54 (119% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.4 | AU$0.71 |
0%
|
| 3-Year Average | 1 | AU$1.54 |
+119%
|
| 5-Year Average | 0.9 | AU$1.36 |
+93%
|
| Country Average | 5.8 | AU$9.33 |
+1 223%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
33.2m AUD | 0.4 | 11.5 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 599.5 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
178B USD | 11.6 | 26 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.6B USD | 9.5 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 32.4 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
326.9B CNY | 13.5 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.5B CHF | 10.1 | -119.8 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 9.2 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.3B USD | 16.4 | 47.2 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD | 7.1 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 11.7 | 29.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 3.4 |
| Median | 5.8 |
| 70th Percentile | 11.1 |
| Max | 27 768.2 |
Other Multiples
EZZ Life Science Holdings Ltd
Glance View
EZZ Life Science Holdings Ltd. engages in wholesale distributor of skin care products under the EAORON brand to pharmacies, supermarkets and specialist retailers. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-03-03. The firm is wholesale distributor of EAORON skin care products for the Australian and New Zealand markets. The company develops, manufactures and distributes genetic technology enabled consumer health products under its own brand, EZZ. The EAORON brand comprises of five product lines, including Hyaluronic Series, Facial Mask Series, Crystal White Series, Specific Care Series and Anti-Sugar Series. The EZZ products cover market segments, including vitamin and dietary supplements, sports nutrition, wright management and wellbeing, herbal/ traditional and pediatric consumer health products.
